Sabinsa Corporation released a position paper demonstrating the scientifically validated safety of the company’s branded Curcumin C3 Complex, in light of a recently published scientific article that questioned the safety of “turmeric”.
An article published by the “American Journal of Clinical Nutrition” reporting high levels of oxalate in some commercial samples of turmeric led to speculation that supplements containing turmeric extract may increase the risk of kidney stone formation in susceptible individuals.
Sabinsa Corporation scientists analyzed samples of the company’s Curcumin C3 Complex for the presence of oxalate. The amount of oxalic acid in a dose of Curcumin C3 Complex is 88 times lower than the lowest level needed for a food to be classified as “high oxalate”.
Their conclusion is that Curcumin C3 Complex is not a significant source of oxalates, and does not increase the risk on kidney stone formation. The position paper can be downloaded at Sabinsa’s product sites, www.curcuminc3complex.com or www.curcuminoids.com.
Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past 20 years, Sabinsa has brought to market more than 100 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full time scientists conducting ongoing research in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. All products intended for human consumption are certified Kosher, with some certified Halal. For more information, visit www.sabinsa.com & www.sabinsacosmetics.com